Evidence map›Paper›PMID 38687180›Full record

ArticleJournal of the American Chemical Society2024

Quantum Defect Sensitization via Phase-Changing Supercharged Antibody Fragments.

Mijin Kim, James J McCann, Jacob Fortner, Ewelina Randall, Chen Chen, Yu Chen, Zvi Yaari, YuHuang Wang, Ronald L Koder, Daniel A Heller

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Writing DNA Bases into spResearch square · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Optical Bionanosensors for Sepsis Diagnostics.Small (Weinheim an der Bergstrasse, Germany) · 2025
    Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mijin KimMolecular Pharmacology Program, Sloan Kettering Institute, New York, New York 10065, United States.ORCID 0000-0002-7781-9466
James J McCannDepartment of Physics, City College of New York, New York, New York 10031, United States.
Jacob FortnerDepartment of Chemistry and Biochemistry, University of Maryland, College Park, Maryland 20742, United States.
Ewelina RandallMolecular Pharmacology Program, Sloan Kettering Institute, New York, New York 10065, United States.
Chen ChenMolecular Pharmacology Program, Sloan Kettering Institute, New York, New York 10065, United States.
Yu ChenDepartment of Physics, City College of New York, New York, New York 10031, United States.
Zvi YaariMolecular Pharmacology Program, Sloan Kettering Institute, New York, New York 10065, United States.
YuHuang WangDepartment of Chemistry and Biochemistry, University of Maryland, College Park, Maryland 20742, United States.ORCID 0000-0002-5664-1849
Ronald L KoderDepartment of Physics, City College of New York, New York, New York 10031, United States.ORCID 0000-0003-0868-4972
Daniel A HellerMolecular Pharmacology Program, Sloan Kettering Institute, New York, New York 10065, United States.ORCID 0000-0002-6866-0000

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Training and Career Development CoreU54CA132378 · NCI · CITY COLLEGE OF NEW YORK · PI Tim Alan Ahles, ADRIANA ESPINOSA · 2008 to 2026
$28.9M
Training and Career Development and Education CoreU54CA137788 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ADRIANA ESPINOSA, FRANCESCA M GANY · 2008 to 2026
$28.1M
Nanosensor Array Platform to Capture Whole Disease FingerprintsR01EB033651 · NIBIB · SLOAN-KETTERING INST CAN RESEARCH · PI Daniel Alan Heller · 2023 to 2026
$2.6M
Machine Perception Nanosensor Array Platform to Capture Whole Disease Fingerprints of Early Stage Pancreatic CancerR00EB033580 · NIBIB · GEORGIA INSTITUTE OF TECHNOLOGY · PI Mijin Kim · 2024 to 2026
$692k
NCI NIH HHS P30 CA008748NCI NIH HHS U54 CA132378NCI NIH HHS U54 CA137788NIBIB NIH HHS R00 EB033580NIBIB NIH HHS R01 EB033651
6 · The paper itself

Abstract

Quantum defects in single-walled carbon nanotubes promote exciton localization, which enables potential applications in biodevices and quantum light sources. However, the effects of local electric fields on the emissive energy states of quantum defects and how they can be controlled are unexplored. Here, we investigate quantum defect sensitization by engineering an intrinsically disordered protein to undergo a phase change at a quantum defect site. We designed a supercharged single-chain antibody fragment (scFv) to enable a full ligand-induced folding transition from an intrinsically disordered state to a compact folded state in the presence of a cytokine. The supercharged scFv was conjugated to a quantum defect to induce a substantial local electric change upon ligand binding. Employing the detection of a proinflammatory biomarker, interleukin-6, as a representative model system, supercharged scFv-coupled quantum defects exhibited robust fluorescence wavelength shifts concomitant with the protein folding transition. Quantum chemical simulations suggest that the quantum defects amplify the optical response to the localization of charges produced upon the antigen-induced folding of the proteins, which is difficult to achieve in unmodified nanotubes. These findings portend new approaches to modulate quantum defect emission for biomarker sensing and protein biophysics and to engineer proteins to modulate binding signal transduction.

Indexed as

Quantum TheoryHumansInterleukin-6Intrinsically Disordered ProteinsNanotubes, CarbonProtein FoldingSingle-Chain AntibodiesInterleukin-6Intrinsically Disordered ProteinsNanotubes, CarbonSingle-Chain Antibodies

Identifiers

PMID38687180
PMCPMC11498269

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.